Arvinas, Inc.

NasdaqGS ARVN

Arvinas, Inc. EBIT for the Trailing 12 Months (TTM) ending September 30, 2024

Arvinas, Inc. EBIT is NA for the Trailing 12 Months (TTM) ending September 30, 2024. EBIT means earnings before interest and taxes, it is calculated as operating income plus non-operating income.

Arvinas, Inc. EBIT for the Trailing 12 Months (TTM) ending September 30, 2023 was USD -305.30 M, a -25.96% change year over year.
Arvinas, Inc. EBIT for the Trailing 12 Months (TTM) ending September 30, 2022 was USD -242.38 M, a -32.18% change year over year.
Arvinas, Inc. EBIT for the Trailing 12 Months (TTM) ending September 30, 2021 was USD -183.37 M, a -85.66% change year over year.
Arvinas, Inc. EBIT for the Trailing 12 Months (TTM) ending September 30, 2020 was USD -98.77 M, a -51.40% change year over year.

Key data

Date	EBIT	EBITDA	Net Income	EPS (Diluted)

NasdaqGS: ARVN

Arvinas, Inc.

CEO	Dr. John G. Houston Ph.D.
IPO Date	Sept. 27, 2018
Location	United States
Headquarters	5 Science Park
Employees	445
Sector	Health Care
Industries Pharmaceuticals Biotechnology

Description

Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC); ARV-471, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer; and ARV-766 an investigational orally bioavailable PROTAC protein degrader for the treatment of men with mCRPC. The company has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., and Bayer AG. Arvinas, Inc. was founded in 2013 and is based in New Haven, Connecticut.

Key trends

Past 5 years